6.7163
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Astria Therapeutics Inc Borsa (ATXS) Ultime notizie
What analysts say about Astria Therapeutics Inc. stockFree Stock Market Forecast Reports - Autocar Professional
What drives Astria Therapeutics Inc. stock priceConsistent double returns - Autocar Professional
Astria Therapeutics Inc. Stock Analysis and ForecastHigh-octane financial growth - jammulinksnews.com
Is Astria Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com
Published on: 2025-07-19 19:06:02 - jammulinksnews.com
Will Astria Therapeutics Inc. stock split in the near futureFree Stock Market Trend Analysis - Newser
why astria therapeutics inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser
How Astria Therapeutics Inc. stock performs during market volatilityTechnical Breakout List - Newser
Why Astria Therapeutics Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - beatles.ru
What makes Astria Therapeutics Inc. stock price move sharplyFree Access to Stock Community - beatles.ru
Astria: Betting On Navenibart In The Crowded HAE Arena - Seeking Alpha
Astria Therapeutics (ATXS) Soars 5.62% on Positive Trial Results - AInvest
Astria Therapeutics Inc (ATXS) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - BioSpace
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Buy” by Analysts - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 - BioSpace
Trading (ATXS) With Integrated Risk Controls - news.stocktradersdaily.com
(ATXS) Trading Report - news.stocktradersdaily.com
Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - BioSpace
Astria Therapeutics to Participate in Upcoming Oppenheimer Innov - GuruFocus
Astria CEO Discusses Breakthrough Dermatology Treatments at Major Oppenheimer Summit - Stock Titan
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - BioSpace
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $30.00 - Defense World
HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):